Summary
The paper analyses the protective or aggravating effect of a purified bacterial polysaccharide in Col.-SK.-Encephalomyelitis and infectious ectromelia in mice, as a function of the method of treatment. Both infections are influenced in a largely similar manner with a typical pattern of variation in the host resistance optimal effects depending on characteristic dose/time relations.
References
R. Meier, P. A. Desaulles undB. Schär, Arch. exp. Path. Pharm.224, 104 (1955).
R. Meier, H. J. Bein undR. Jaques, Exper.12, 235 (1956).
R. Meier undL. Neipp, Schweiz. med. Wschr.86, 249 (1956).
M. Landy, Fed. Proc.15, 598 (1956).
O. A. Ross, N. Y. Acad. Sci.66, 274 (1956).
D. Rowley, N. Y. Acad. Sci.66, 304 (1956).
J. S. Kiser, H. Lindh undG. C. de Mello, N. Y. Acad. Sci.66, 312 (1956).
R. Meier undF. Kradolfer, Exper.12, 213 (1956).
F. L. Horsfall undM. McCarthy, J. exp. Med.85, 623 (1947).
H. S. Ginsberg undF. L. Horsfall, J. exp. Med.93, 161 (1951).
Das Präparat wurde in den chemischen Forschungslaboratorien der CIBA Aktiengesellschaft, Basel, von Dr.F. W. Kahnt hergestellt.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kradolfer, F., Wyler, R. & Meier, R. Abhängigkeit der Antiviruswirkung bakterieller Polysaccharide von Behandlungstermin, Behandlungsdosis und Infektionsstärke. Experientia 13, 187–189 (1957). https://doi.org/10.1007/BF02157152
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02157152